Ontology highlight
ABSTRACT:
SUBMITTER: Amaria RN
PROVIDER: S-EPMC6481682 | biostudies-literature | 2018 Nov
REPOSITORIES: biostudies-literature
Amaria Rodabe N RN Reddy Sangeetha M SM Tawbi Hussein A HA Davies Michael A MA Ross Merrick I MI Glitza Isabella C IC Cormier Janice N JN Lewis Carol C Hwu Wen-Jen WJ Hanna Ehab E Diab Adi A Wong Michael K MK Royal Richard R Gross Neil N Weber Randal R Lai Stephen Y SY Ehlers Richard R Blando Jorge J Milton Denái R DR Woodman Scott S Kageyama Robin R Wells Daniel K DK Hwu Patrick P Patel Sapna P SP Lucci Anthony A Hessel Amy A Lee Jeffrey E JE Gershenwald Jeffrey J Simpson Lauren L Burton Elizabeth M EM Posada Liberty L Haydu Lauren L Wang Linghua L Zhang Shaojun S Lazar Alexander J AJ Hudgens Courtney W CW Gopalakrishnan Vancheswaran V Reuben Alexandre A Andrews Miles C MC Spencer Christine N CN Prieto Victor V Sharma Padmanee P Allison James J Tetzlaff Michael T MT Wargo Jennifer A JA
Nature medicine 20181008 11
Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is associated with enhanced survival and antigen-specific T cell responses compared with adjuvant treatment<sup>1</sup>; however, optimal regimens have not been defined. Here we report results from a randomized phase 2 study of neoadjuvant nivolumab versus combined ipilimumab with nivolumab in 23 patients with high-risk resectable melanoma ( NCT02519322 ). RECIST overall response rates (ORR), pathologic comple ...[more]